Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares.

BMO Capital analyst Evan Seigerman raised the firm’s price target on Replimune (REPL) to $27 from $18 and keeps an Outperform rating on the ...

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

Replimune Group ( REPL, Financials) shares surged 17% to $11.85 as of 10:18 a.m. ET Tuesday after the U.S. Food and Drug ...

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ: REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

Replimune Group Inc (REPL) stock saw a modest uptick, ending the day at $11.85 which represents a slight increase of $1.71 or 16.86% from the prior close of $10.14. The stock opened at $12.6 and ...

Evolus Inc EOLS shares jumped 35.6% to $14.25 after the company announced it expects FDA approval for Evolysse gels within 90 ...

Replimune Group Inc has established itself as a leader in the field of oncolytic immunotherapy, with a wholly-owned pipeline and advanced manufacturing facilities. The company's primary focus is ...